Avid Bioservices Inc (CDMO)

[jazzbeerman]

steve,


SK, during the Sept CC,


"we have been working with add’l sites who would like to participate in the [HCV/HIV] trial, and expect to bring those sites online in the near future. We also intend to conduct add’l HCV studies to evaluate new Bavi treatment schedules and to explore its use in combination with existing therapies. Data, even partial data, we will gather from the HCV-HIV study, with its extended treatment duration s/b invaluable in designing these next HCV studies. Both we and our advisors are very pleased with the results generated to-date from the HCV pgm. The potential importance of this pgm was highlighted by the distinction of being selected for an oral presentation at the AASLD Meeting in Nov., one of the most prestigious liver disease meetings in the world.


Our collab. with HIV researchers at Duke remains strong and is making good progress. The collab. is providing exciting, new insights into the potential of Bavi, and other Anti-PS antibodies, in HIV – data which otherwise would be extremely difficult, if not impossible, to generate. We look fwd to reporting on these results at a time our collab’s feel appropriate.

In addition, we recently reported that we are negotiating with the DTRA for a contract which could total over $44mm over the next 5 yrs., to study the potential of Bavi and and other Anti-PS antibodies for the treatment of hemorrhagic fever virus infections [ex: Lassa, Marburg, Ebola]. Negotiations are active, and we remain excited about this unique opportunity to study new uses for the Anti-PS technology, while at the same time helping support our current dev. pgms.


So, what dev’s do we anticipate for the Bavi AV pgm between now and the next CC in Dec.?

• Adding New Clinical Sites to the HCV-HIC Co-Infection Trial
• Significant Progress in the HCV-HIV Trial, Allowing Periodic Updates
• Presenting Final Data from Ph.1 Repeat-Dose HCV Study at AASDL in Nov.
• Completing Contract Negotiations with the DTRA"



------



j